2.20
Alzamend Neuro Inc stock is traded at $2.20, with a volume of 77,378.
It is up +0.92% in the last 24 hours and down -8.71% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$2.18
Open:
$2.23
24h Volume:
77,378
Relative Volume:
0.52
Market Cap:
$6.91M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.329
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
-14.06%
1M Performance:
-8.71%
6M Performance:
-68.14%
1Y Performance:
-85.27%
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALZN
Alzamend Neuro Inc
|
2.20 | 7.50M | 0 | -5.85M | -8.00M | -6.6877 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Will Alzamend Neuro Inc. stock rally after Fed decisionsQuarterly Profit Summary & Reliable Trade Execution Plans - newser.com
Will Alzamend Neuro Inc. stock pay special dividendsEarnings Overview Summary & Step-by-Step Swing Trade Plans - newser.com
Is Alzamend Neuro Inc. stock supported by innovation pipelineJuly 2025 Short Interest & Growth Focused Entry Reports - newser.com
Intraday pattern recognizer results for Alzamend Neuro Inc.Portfolio Return Report & Free Expert Approved Momentum Trade Ideas - newser.com
Real time social sentiment graph for Alzamend Neuro Inc.2025 Market Sentiment & Daily Profit Focused Screening - newser.com
Strategies to average down on Alzamend Neuro Inc.Swing Trade & Daily Price Action Insights - newser.com
Order flow analysis tools used on Alzamend Neuro Inc.Market Volume Summary & Fast Moving Trade Plans - newser.com
Analyzing recovery setups for Alzamend Neuro Inc. investorsDollar Strength & Risk Managed Investment Strategies - newser.com
What recovery options are there for Alzamend Neuro Inc.2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Why Alzamend Neuro Inc. stock is a must watch in 20252025 Key Lessons & Daily Volume Surge Trade Alerts - newser.com
Analyzing drawdowns of Alzamend Neuro Inc. with statistical toolsJuly 2025 Catalysts & Smart Allocation Stock Reports - newser.com
Alzamend Neuro Issues New Common Stock Shares - TipRanks
Alzamend Neuro Inc. stock trend forecast2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Published on: 2025-10-09 05:02:17 - newser.com
Alzamend Neuro Insider Sold Shares Worth $344,222, According to a Recent SEC Filing - 富途牛牛
Ault Milton C III sells Alzamend Neuro (ALZN) shares for $344,222 - Investing.com
Quantitative breakdown of Alzamend Neuro Inc. recent moveJuly 2025 Retail & Verified Momentum Watchlists - newser.com
Sector ETF performance correlation with Alzamend Neuro Inc.Portfolio Gains Report & Reliable Breakout Stock Forecasts - newser.com
Ault Milton C III sells Alzamend Neuro (ALZN) stock worth $296k - Investing.com
How to track smart money flows in Alzamend Neuro Inc.July 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
Published on: 2025-10-05 03:52:11 - newser.com
Applying big data sentiment scoring on Alzamend Neuro Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
Using fundamentals and technicals on Alzamend Neuro Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - newser.com
What institutional flow reveals about Alzamend Neuro Inc.Chart Signals & Proven Capital Preservation Tips - newser.com
Director’s Major Stock Sale Shakes Up Alzamend Neuro! - TipRanks
Applying sector rotation models to Alzamend Neuro Inc.2025 Trading Recap & Precise Trade Entry Recommendations - newser.com
What analysts say about Alzamend Neuro Inc stockBollinger Bands Signals & Affordable Stock Market Tips - earlytimes.in
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alzamend Neuro Inc Stock (ALZN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
AULT MILTON C III | Director |
Sep 29 '25 |
Sale |
2.31 |
38,324 |
88,490 |
35,192 |
AULT MILTON C III | Director |
Sep 26 '25 |
Sale |
2.31 |
37,738 |
87,345 |
73,516 |
AULT MILTON C III | Director |
Sep 30 '25 |
Sale |
2.33 |
3,566 |
8,321 |
31,626 |
AULT MILTON C III | Director |
Sep 23 '25 |
Sale |
2.38 |
43,238 |
102,721 |
65,022 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):